Selective COX inhibitors also reduced systemic levels of TNF-α and IL-1β, in which TNF-α participates in developing and maintaining HPS and TNF-α neutralization improves experimental HPS [2, 26]. This evidence concerns the gene IL1B and Hermansky-Pudlak syndrome.